Eagle Capital Management Bet on Danaher (DHR) for Its Mid-Teens EPS Growth

2 days ago 2

Soumya Eswaran

Thu, May 21, 2026 astatine 9:05 AM CDT 3 min read

Eagle Capital Management, an concern absorption company, released its archetypal 4th 2026 capitalist letter. A transcript of the missive is disposable to download here. The missive notes that idiosyncratic stocks and subsectors are present much reactive to sentiments, reducing marketplace ratio but creating opportunities to adhd value. Over the past decade, multi-asset managers, oregon pods, person grown significantly, operating with leverage, choky hazard controls, and rapidly cutting losers, often relying connected net momentum. Growth managers person outperformed worth managers, attracting flows; retail investors progressively pursuit momentum, reducing wide diverseness and amplifying momentum's influence. It’s much invaluable to find arguable oregon underexplored assets aboriginal and payment arsenic net grow. Eagle has capitalized connected this trend, expecting continued opportunities. Investments should see probabilities, gathering portfolios for assorted outcomes alternatively than betting connected one, which allows for compound growth. The Strategy is generating beardown semipermanent implicit returns. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2026.

In its first-quarter 2026 capitalist letter, Eagle Capital Management highlighted Danaher Corporation (NYSE:DHR) arsenic a recently added position. Danaher Corporation (NYSE:DHR) is simply a healthcare and beingness subject tools institution that operates done Biotechnology, Life Sciences, and Diagnostics segments. On May 20, 2026, Danaher Corporation (NYSE:DHR) closed astatine $171.12 per share. One-month instrumentality of Danaher Corporation (NYSE:DHR) was -4.17%, and its shares mislaid 8.73% implicit the past 52 weeks. Danaher Corporation (NYSE:DHR) has a marketplace capitalization of $118.23 billion.

Eagle Capital Management stated the pursuing regarding Danaher Corporation (NYSE:DHR) successful its Q1 2026 capitalist letter:

"We’ve built a presumption successful Danaher Corporation (NYSE:DHR), a starring beingness sciences company. Danaher sells a wide premix of consumables and tooling that are mission-critical to biologic R&D, diagnostic testing, and biopharma cause production. It has precocious marketplace share, differentiated technology, beardown management, and bully maturation prospects.

Over the past respective years, Covid-related gross disappeared, the biotech end-market boomed and past crashed, China slowed, and NIH backing was cut. As a result, this historically unchangeable grower has been thing but unchangeable oregon growing. It’s present trading astatine a depressed aggregate connected depressed earnings. With lower-quality net flushed retired of the basal and different parts moving beneath trend, we expect improving, and perchance adjacent supra trend, maturation implicit the coming years. Moreover, 1 of the astir breathtaking areas of exploration for AI exertion is successful biopharma research. This has the imaginable to beryllium a medium- to semipermanent accelerant for Danaher’s business. We expect EPS maturation successful the mid-teens."

Read Entire Article